Technology, Healthcare May 28, 2021 12:29 PM (GMT+8) · EqualOcean
The research report issued by CSCI maintains the "buy" rating of IgG with a target price of HK $19.6. It is estimated that the revenue in 2021-22 will be RMB 5.976 billion and RMB 7.470 billion, and the net profit attributable to the parent company will be RMB 1.2 billion and RMB 1.5 billion. The report points out that the company's R & D rate and sales rate may be further increased in the first half of 2021 due to the growth of R & D investment and purchasing investment. But in the long run, the company's investment growth is conducive to the long-term, sustainable and healthy development of the business. With the continuous launch of many new games in the future and the continuous rise of the flow, the company's future performance is expected to be further released.

This text is a result of machine translation.

Related companies：